Targets › FKRP
3 programs from 3 companies in 5 trials: 2 Phase 1, 2 Phase 3, 1 Phase 2; Neurology; next expected readout Nov 2026.
Catalyzes the transfer of a ribitol 5-phosphate from CDP-L-ribitol to the ribitol 5-phosphate previously attached by FKTN/fukutin to the phosphorylated O-mannosyl trisaccharide (N-acetylgalactosamine-beta-3-N-acetylglucosamine-beta-4-(phosphate-6-)mannose), a carbohydrate structure present in alpha-dystroglycan (DAG1). This constitutes the second step in the formation of the ribose 5-phosphate tandem repeat which…. (UniProt, Q9H9S5)
Open in Phaseline: the race on FKRP, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| ML Bio Solutions | BBP-418 substrate supplementation to enhance glycosylation of muscle α-dystroglycan | FKRP | Phase 3 | Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I); LGMD2I | Nov 2026 |
| AskBio | AB-1003 Gene therapy delivering functional FKRP gene | FKRP | Phase 1 | Limb Girdle Muscular Dystrophy | Dec 2028 |
| Atamyo Therapeutics | ATA-100 AAV9 gene therapy delivering FKRP gene | FKRP | Phase 1 | LGMDR9 | Sep 2029 |
Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I) (2) Limb Girdle Muscular Dystrophy (1) LGMD2I (1) LGMDR9 (1)
other (2), small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.